医学
临床终点
肺癌
临床试验
外科
腺癌
机构审查委员会
癌症
知情同意
专业
随机对照试验
内科学
病理
替代医学
作者
Shiqi Chen,Qingyuan Huang,Fangqiu Fu,Zezhou Wang,Yang Zhang,Haiquan Chen
出处
期刊:BMJ Open
[BMJ]
日期:2024-07-01
卷期号:14 (7): e087088-e087088
标识
DOI:10.1136/bmjopen-2024-087088
摘要
Introduction Previous studies demonstrated that wedge resection is sufficient for ground glass-dominant lung adenocarcinoma (LUAD) with tumour diameter ≤2 cm, however, the optimal surgical type for ground glass-dominant LUAD with tumour diameter of 2–3 cm remains unclear. The purpose of this trial is to investigate the safety and efficacy of segmentectomy for ground glass-dominant invasive LUAD with tumour size of 2–3 cm. Methods and analysis We initiated a phase III trial to investigate whether segmentectomy is suitable for ground glass-dominant invasive LUAD with tumour size of 2–3 cm. This trial plans to enrol 307 patients from multiple institutions including four general hospitals and two specialty cancer hospitals over a period of 5 years. The primary endpoint is 5 year disease-free survival. Secondary endpoints are lung function, 5 year overall survival, the site of tumour recurrence and metastasis, segmentectomy completion rate, radical segmentectomy (R0 resection) completion rate and surgery-related complications. Ethics and dissemination This trial has been approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (reference 2212267-18) and by the institutional review boards of each participating centre. Written informed consent is required from all participants. The study results will be published in a peer-reviewed international journal. Trial registration number NCT05717803 .
科研通智能强力驱动
Strongly Powered by AbleSci AI